MacroGenics, Inc. (FRA:M55)
Germany · Delayed Price · Currency is EUR | Market Cap | 127.99M +16.4% |
| Revenue (ttm) | 153.30M +21.7% |
| Net Income | -12.77M |
| EPS | -0.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Open | 3.200 |
| Previous Close | 3.180 |
| Day's Range | 3.200 - 3.200 |
| 52-Week Range | 1.137 - 4.220 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG... [Read more]
Financial Performance
In 2025, MacroGenics's revenue was $149.50 million, a decrease of -0.31% compared to the previous year's $149.96 million. Losses were -$74.62 million, 11.4% more than in 2024.
Financial numbers in USD Financial StatementsNews
MacroGenics announces interim data from LINNET study evaluating lorigerlimab
MacroGenics (MGNX) announced interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2…
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics announces interim data from MGC026 study
MacroGenics (MGNX) announced interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, or ADC, in patients with advanced solid tumors. These Phase 1 data were pr...
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics doses first patient in MGC030 study
MacroGenics (MGNX) announced that the first patient has been dosed in the Phase 1 study of MGC030, an antibody-drug conjugate directed against an undisclosed target, in patients with advanced solid…
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A year of transformation saw a streamlined organization, major divestiture, and robust financial strengthening. The pipeline advanced with multiple first-in-class ADCs and T-cell engagers, while key partnerships and non-dilutive funding secured a cash runway through 2028.
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
MacroGenics price target raised to $11 from $9 at B. Riley
B. Riley raised the firm’s price target on MacroGenics (MGNX) to $11 from $9 and keeps a Buy rating on the shares following the Q2 report. The firm believes the…
MacroGenics reports Q2 EPS 31c, consensus 26c
Reports Q2 revenue $32.83M, consensus $59.14M. “Our team delivered strong second-quarter execution: advancing our strategic priorities, strengthening our financial position, and sharpening our focus t...
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the trea...
MacroGenics Earnings release: Q2 2026
MacroGenics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MacroGenics Quarterly report: Q2 2026
MacroGenics has published its Q2 2026 quarterly earnings report on August 13, 2026.
MacroGenics Slides: Corporate presentation
MacroGenics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics provides update on MGC026 study
MacroGenics (MGNX) provided an update on the ongoing Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, incorporating a topoisomerase I inhibitor-based linker-payload, in patie...
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enro...
MacroGenics Slides: Corporate presentation
MacroGenics has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2026.
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics to receive $24.5M milestone payment from Sanofi
MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s accelerated approval of TZIELD to delay the ...
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Significant non-dilutive capital from royalty and manufacturing deals extends runway through 2028, enabling robust investment in a diversified oncology pipeline. Key clinical updates for ADC and bispecific programs are expected in 2024, with a focus on innovation and strategic partnerships.
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, ...
MacroGenics reports Q1 EPS (58c), consensus (55c)
Reports Q1 revenue $20.78M, consensus $15.24M. “We are very pleased to report a strong start to the year, building on the momentum generated in 2025. These results reflect our team’s…
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...